GL
DGX icon

Graypoint LLC’s Quest Diagnostics DGX Stock Holding History

Graypoint LLC’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$209K Buy
+1,162
New +$202K 0.01% 505

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Graypoint LLC's DGX Position: Q2 2025 in Review

Graypoint LLC opened a new position in Quest Diagnostics (DGX) in Q2 2025: 1,162 shares worth $209K. The stake represents 0.01% of the portfolio and ranks #505 among its holdings.

990 funds tracked by Wall St. Rank hold DGX as of Q2 2025.

  • Graypoint LLC held 1,162 shares of Quest Diagnostics worth $209K as of Q2 2025.
  • Quest Diagnostics was a new Graypoint LLC position in Q2 2025.
  • Quest Diagnostics made up 0.01% of Graypoint LLC's portfolio in Q2 2025, its #505 holding.
  • 990 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.